Sun.Feb 11, 2024

article thumbnail

Fierce Healthcare Fundraising Tracker—Ezra picks up $21M backed by Former One Medical CEO's VC

Fierce Healthcare

A new year brings a new approach to tracking health tech and digital health investments. | Each week, Fierce Healthcare will publish a roundup of health tech and digital health financing rounds.

96
article thumbnail

Pfizer/BioNTech COVID jab to be sold privately in UK

pharmaphorum

MHRA license change means people in GB will be able to buy Pfizer’s COVID-19 vaccine Comirnaty at retail pharmacies from March

Vaccines 109
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novolog Versus Fiasp Insulin Comparison

Med Ed 101

With many insulin formulations on the market, it can be hard to differentiate between similar-acting products and what the best choice may be for our patients. One question raised is what the differences between Novolog versus Fiasp are due to both being insulin aspart formulations. The main difference is right in the name of Fiasp. […] The post Novolog Versus Fiasp Insulin Comparison appeared first on Med Ed 101.

52
article thumbnail

Avoid Clinical Manufacturing Pitfalls With These 4 Tech Transfer Best Practices

BioPharm

Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST

52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

The FDA Law Blog

By Larry K. Houck — With apologies to David Letterman, who introduced the first Top Ten List on Late Night with David Letterman on September 18, 1985, we present “Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not.”* The wide range of assertions supporting or opposing Health and Human Services’ (“HHS’”) recommendation that the Drug Enforcement Administration (“DEA”) reschedule cannabis federally from schedule I to schedule III would lead an outsider to conclude that commenters are